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Abstract Secretin and its receptors show wide distribution
in the central nervous system. It was demonstrated previously
that intravenous (i.v.) and intracerebroventricular (i.c.v.)
application of secretin influenced the behavior of rat,
mouse, and human. In our previous experiment, we used
a special animal model, Japanese waltzing mice (JWM).
These animals run around without stopping (the ambulation
distance is very limited) and they do not bother with their
environment. The i.c.v. secretin attenuated this hyperactive
repetitive movement. In the present work, the effect of i.c.v.
and intranasal (i.n.) application of secretin was compared. We
have also looked for the presence of secretin receptors in the
brain structures related to motor functions. Two micrograms
of i.c.v. secretin improved the horizontal movement of JWM,
enhancing the ambulation distance. It was nearly threefold
higher in treated than in control animals. The i.n. application
of secretin to the left nostril once or twice a day or once for
3 days more effectively enhanced the ambulation distance
than i.c.v. administration. When secretin was given twice
a day for 3 days it had no effect. Secretin did not improve
the explorative behavior (the rearing), of JWM. With the
use of in situ hybridization, we have found very dense
secretin receptor labeling in the cerebellum. In the primary
motor cortex and in the striatum, only a few labeled cells
were seen. It was supposed that secretin exerted its effect
through specific receptors, mainly present in the
cerebellum.
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Introduction
Secretin in the nervous system was first demonstrated in the
forebrain and brain stem using radioimmunoassay and high-
pressure liquid chromatography (Charlton et al. 1981). In
the rat cerebellar Purkinje cells secretin and its mRNA were
first demonstrated by Yung et al. (2001) using in situ hybrid-
ization. A few years later, secretin was also demonstrated in
human cerebellum (Lee et al. 2005). Later we found secretin
immunoreactivity in the Purkinje cells, central cerebellar
nuclei, pyramidal cells of cortex, hippocampus, amygdala,
and in sensory ganglia of the rat, cat, and human (Köves et
al. 2002, 2004). Secretin mRNA was demonstrated in the
trigeminal ganglion (Heinzlmann et al. 2011). Two questions
arises: what is the function of secretin and where is the site of
action of secretin in the central nervous system?
Function of Secretin in the Central Nervous System
At the first time, the effect of secretin on the behavior of rats
was also demonstrated by Charlton et al. (1983). Secretin
administered intracerebroventricularly (i.c.v.) to rats de-
creased the novel object approach and the open field loco-
motor activity, however, did not influence the rearing. In our
previous experiment (Köves et al. 2011), we studied the
effect of secretin administered i.c.v. on the behavior of two
mouse strains. The response to secretin of CFLP white mice
and Japanese waltzing mice (JWM) was compared. CFLP
mice are usually used for testing the effect of various drugs
on the behavior. JWM were included because they exhibit
repetitive movement, which is characteristic for several
mental disorders, especially for autistic children. These ani-
mals run around in their cage nearly without stopping not
bothering their environment. Their ambulation distance is
much lower than that of CFLP mice. The data showed that
secretin influenced the locomotor activity of the above-
mentioned special animal model. Its effect on the repetitive
movement was beneficial. It enhanced ambulation distance
to the level of CFLP mice, although it did not improve the
explorative behavior of the animals (rearing). It has also
become evident that secretin is synthesized in supraoptic
(SO) and paraventricular (PV) nuclei (Welch et al. 2004) and
it regulates water homeostasis (Chu et al. 2009). In PV, there
may be an interaction between secretin and corticotropic
hormone-releasing hormone (Welch and Ruggiero 2005).
More than a decade ago, it was found that secretin counteracts
the analgesic effect of morphine (Babarczy et al. 1995).
Site of Action of Secretin in the Central Nervous System
The site of action of secretin was investigated to induce
c-Fos activation by administration of secretin or to
demonstrate secretin receptors. Intravenous (i.v.) infusion of
secretin to rats induced c-Fos gene expression in the central
amygdala, area postrema, bed nucleus of stria terminalis,
external lateral parabrachial, and SO (Goulet et al. 2003).
After i.c.v. administration of secretin, many regions such as
several brain stem, hypothalamic and limbic structures (sep-
tum and amygdala), the medial bank of the anterior prefrontal,
orbitofrontal, and the piriform cortex showed activation of Fos
protein in awake, freely moving rats (Welch et al. 2003). It is
clear from the above-mentioned data that secretin influences
c-Fos expression in structures that are involved in behavior,
stress adaptation, and visceral responses. There is a limited
number of papers in the literature which demonstrated the
presence of secretin receptors in the structures where secretin
induced c-Fos expression or appearance of Fos protein.
Fremeau et al. (1983) using radioreceptor assay found
secretin binding in the cerebellum, cortex, thalamus, striatum,
hippocampus, hypothalamus, and the brain stem. Nozaki et al.
(2002) found in vitro I125-secretin binding in the nucleus of
solitary tract (NST), laterodorsal thalamus, accumbens nucle-
us, hippocampus, cerebellum, cingulate, and orbital cortex.
Tay et al. (2004) using polymerase chain reaction found the
highest secretin receptor level in the cerebellum, although it
was also present in NST, amygdala, hippocampus, and area
postrema. Cheng et al. (2011) using in situ hybridization
described the presence of secretin receptors in PVand arcuate
nucleus. Yung et al. (2001) were able to show secretin recep-
tors in the basket and Purkinje cells of the cerebellar cortex.
Intranasal Application of Peptides
In the last two decades, some peptides such as cholecysto-
kinin (Pietrowsky et al. 1996, 2001; Born et al. 2002; Illum
2004; Schneider et al. 2009), thyreotropic hormone-releasing
hormone (Kubek et al. 2009) and insulin (Guthoff et al. 2010)
were shown to be delivered to the brain by intranasal (i.n.)
application. In a recent work, Nonaka et al. (2009) demonstrated
that pituitary adenylate cyclase-activating polypeptide applied
i.n. could be delivered to the brain and its distribution might be
influencedwith coadministration ofα- or hydro-β-cyclodextrin.
It was also shown that an iodinated secretin analogue could
enter the brain from the nose (Banks et al. 2002).
Aim of Experiments
1. The first aim of our present experiment was to elaborate
the i.n. application of secretin in JWM mice. The ad-
vantage of this method that it is not invasive and it could
be easily used not only in adult patients but in children
as well who have mental disorders.
2. The second aim was to compare the effect of secretin
administered i.c.v. and i.n. Open field test was used to
investigate the effect of secretin on the behavior of
JWM.
J Mol Neurosci (2012) 48:558–564 559
3. The third aim of this experiment was to demonstrate
secretin receptors in areas which are related to mo-
tor functions. We have used in situ hybridization in
rats.
Materials and Methods
Animals Adult (3–4 month old) female JWM were used for
the behavior experiments and Sprague-Dawley adult male
rats were used to look for secretin receptors. The animals
were kept in a light- and temperature-controlled vivarium
(lights on at 500 hours and lights off at 1900 hours; temper-
ature 22±2 °C). Treatment of animals was in accordance
with the rules of the “European convention for the
protection of vertebrate animals used for experimental
and other scientific purposes” (Strasbourg, 1986; per-
mission #: 22.1/1158/2010).
Administration of Secretin One hundred micrograms of
secretin (Sigma-Aldrich, St. Louis, MO) was dissolved in
5 μl acetic acid+20 μl distilled water. Then to the 25-μl
solution, containing 100 μg secretin, 75 μl physiological
saline or artificial cerebrospinal fluid was added. The final
concentration was 1 μg/μl secretin.
1. Intracerebroventricular application. Under general
hexobarbital anesthesia (0.08 mg/gr BW), a guiding
cannula was implanted in the lateral ventricle of ten
JWM. A day later to five animals, 2 μg secretin in
2 μl artificial cerebrospinal fluid was administered
through the cannula. The rest of the animals received
only cerebrospinal fluid.
2. Intranasal application through a bougie. The needle of a
Hamilton syringe (10 μl) was equipped with a piece of
polyethylene tube (length 3.5 mm, inner diameter 0.015
in,, outer diameter 0.043 in.). Ten JWM received 2 μg
secretin in 2 μl physiological saline and it was sprayed
into the left nostril by the syringe. Five animals received
2 μl physiological saline.
3. Intranasal application in pulverized form. Nine JWM
received 2 μg secretin in 2 μl physiological saline in
pulverized form once or twice in three succeeding days.
Four animals served as controls. According to the sim-
ilar schedule, they received physiological saline.
The effect of secretin on behavior of the animals was
examined using an open field test.
Behavior Test The open field apparatus was a square open
field black cage with a side length of 60 cm, surrounded by a
40-cm high wall. The floor of the cage was divided in 36
(6×6) small squares. A 60-W light was situated 1 m above
the arena floor. Sessions started at 9 a.m. All animals were
carried to the experimental room in their home cage. Each
animal was placed in the center of the open field and was
observed for 30 min. Conducta 1.0 system (Experimetria
Ltd., Budapest, Hungary) was used for monitoring the ani-
mals and analyzing the data. The horizontal locomotor
activity defined as ambulation distance and the vertical
movement defined as rearing were evaluated. Statistical
analysis of the data was made by repeated measure analysis
of variance (ANOVA). For significant ANOVA values,
groups were compared by Tukey's test as post test. A
probability value, p<0.05 was considered statistically
significant.
In Situ Hybridization
1. Five animals were decapitated; the brain was imme-
diately removed and stored at −70 °C until use.
Twelve-micrometer thick sections were cut on cryo-
stat (Cryotome, Thermo Shandon, Pittsburg, PA),
mounted on silanized slides, and dried on a hot
plate (37 °C).
2. The 453-base pair-long fragment (Ishihara et al. 1991)
was shortened and subcloned into a pBluescript II SK
(+) vector and verified by sequencing. Antisense and
sense cRNA probes, labeled by [35S] uracil triphosphate
and used for in situ hybridization, were produced by
vitro transcription.
3. Before hybridization sections were washed and then
treated with 0.25 % acetic anhydride in 0.1 M
triethanolamine HCl (pH 8.0) for 10 min. After
hybridization, the sections were rinsed in 0.3 M
NaCl–0.03 M sodium citrate solution (2× SSC),
dehydrated and delipidated in a subsequent series
of 70, 85, 95, 100, and 95 % ethanol, and finally
air-dried. Hybridization was performed overnight at
55 °C with 106 cpm/slide radioactively labeled se-
cretin receptor riboprobe in a humid chamber. The
following day, the sections were washed in 4× SSC
buffer (pH 7.0) for 4×5 min at room temperature;
then they were treated in RnaseA (20 μg/ml; Sigma,
Budapest, Hungary) buffer (pH 8.0) containing
500 mM NaCl, 10 mM Tris–HCl, and 0.25 mM
ethylenediaminetetraacetic acid for 30 min at 37 °C, then
for 5 min in each of the following buffer solutions: 2×
SSC, 1× SSC, and 0.5× SSC at room temperature; and
finally in 0.1× SSC at 65 °C for 2×30min. Then the slides
were let to cool down and washed in 1× PBS (pH 7.4).
The slides were dipped into NTB3 nuclear track emulsion
(Eastman Kodak Co., Rochester, N.Y.). After 21 days of
exposition time at 4 °C in dark, the reaction was devel-
oped using Kodak Dektol developer and fixer at 18 °C.
4. The slides were counterstained with Giemsa solution,
dried, and coverslipped with DePeX.
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Results
Effect of Secretin on the Behavior
The effect of i.c.v. and i.n. application of secretin to the
animals was compared.
1. The i.c.v. application of secretin significantly influenced
the horizontal movement of the animals. It enhanced the
ambulation distance. It was more than twofold higher
than in control animals (Fig. 1a). Rearing in untreated
JWM is very low, and the animals do not bother about
their environment. The i.c.v. application of secretin did
not improve this parameter (Fig. 1b).
2. The i.n. application of secretin, sprayed into the left
nostril once or twice a day, was even more effective
enhancing the ambulation distance in the experimental
animals than the i.c.v. application (Fig. 2a), but it was
not able to influence the rearing similarly to i.c.v appli-
cation (Fig. 2b).
3. The i.n. application of secretin in pulverized form
through a bougie in the left nostril once or twice for
3 days had contrasting effect. Once a day administration
(three times all together) enhanced the ambulation dis-
tance in the experimental animals similarly to the single
i.n. administration. The ambulation distance was also
higher than in controls (Fig. 3a). When secretin was
administered twice a day for 3 days, that is, when it
was overdosed (six times all together), it had no effect
and the ambulation distance was similar to that of the
control animals. None of these treatments could influ-
ence the rearing (Fig. 3b).
Secretin Receptors in Structures Related to Motor Functions
In the primary motor cortex, we found a few, weekly labeled
secretin receptor-expressing cells. They were seen in the
median frontal gyrus. In the head of caudate nucleus (stria-
tum), similarly to the frontal gyrus, a few very weekly
labeled cells were observed (not shown). However, in the
cerebellum, a very dense secretin receptor expression was
found. The labeling was denser in the hemispheres (Fig. 4a)
than in the vermis (Fig. 4b). As it was expected, many labeled
cells were observed in the cortex, but the labeling was not
observed in the central cerebellar nuclei. The majority of the
labeled cells were found in the granule cell layer. Figure 4c–f
shows secretin-expressing cells in this layer. Purkinje cells
were rarely labeled (Fig. 4d). Figure 4e clearly shows the
place of unlabeled Purkinje cells. By chance we could see
the labeled cells in the molecular layer as well (Fig. 4e). In
Fig. 4f, very weekly labeled cells are shown in the granule cell
layer of the vermis.
Discussion
The regulation of the behavior of animals is a very complex
process; many structures of the nervous system are involved
in this mechanism. They exert their effect through neuro-
peptides and neurotransmitters. One of these peptides may
be the secretin. The presence of secretin in the central
nervous system and the effect of secretin on the behavior
became evident in the last three decades as it was described
in the “Introduction.”
To better understand the neuroactive role of secretin in
the brain, Yamagata et al. (2008) have recently generated
secretin-deficient mice. Exon 1 of the secretin receptor was
replaced with lacZ reporter and PGKneobpA selection mark-
er. In mutant mice, lacZ reporter was demonstrated in the
molecular layer of the hippocampus, dentate gyrus,
Fig. 1 a The diagram shows the quantitative analysis of the horizontal
movement of the animals after 2 μg of i.c.v. secretin. Ambulation
distance is expressed in centimeters for 30 min. *p<0.05. b The
vertical movement, that is the number of rearing, was not influenced
by i.c.v. administration of secretin
Fig. 2 a The diagram shows the quantitative analysis of the horizontal
movement of the animals after 2 μg of i.n. administration of secretin
through a bougie and is expressed in centimeters for 30 min. Secretin
given once or twice a day enhanced the ambulation distance. *p<0.05.
b Number of rearing of the animals was not influenced at all
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posterior commissure, habenula, cerebellum, olfactory glo-
meruli, and the dorsal tegmentum. No obvious morpholog-
ical and developmental abnormalities were found in the
brain of these animals. Electrophysiological examination
was only carried out in the hippocampus using electrophys-
iological approach. A reduction in LTP induction and LTP
maintenance was found. These results suggest that both
secretin and its receptor are necessary for normal hippocam-
pal function. The effect of secretin is probably mediated
through the glutamate, an excitatory amino acid, critical
for LTP. This hypothesis is supported by the findings of
Kuntz et al. (2004) who demonstrated that secretin increased
glutamate and γ-amino butyric acid (GABA) levels in the
rat hippocampus using microdialysis technique.
The effect of secretin may be mediated via the structures
of the nervous system where secretin receptors are found. It
is well known that the cerebellum coordinates the motor
activity of the organism. Both secretin and its receptors were
demonstrated by Yung et al. (2001, 2006). In the cerebel-
lum, secretin facilitates the GABAergic inhibitory inputs
onto Purkinje cells via a postsynaptic- and cAMP-
dependent mechanism as a retrograde messenger. The
Fig. 3 a The diagram shows the quantitative analysis of the horizontal
movement of the animals after 2 μg of i.n. administration of secretin in
pulverized form once or twice for 3 days (three times or six times).
Ambulation distance is expressed in centimeters for 30 min. Secretin
given three times enhanced, but given six times did not influence, the
ambulation distance. *p<0.05. b Secretin did not influence the rearing
in these animal groups
Fig. 4 Microphotographs show
secretin-expressing neurons in
the cerebellar cortex. a Two
folia in the left hemisphere.
Black spots indicate secretin
receptor-expressing cells. b
Two folia in the vermis (a and
b) and one in the right hemi-
sphere (c). c–e High-power
details of the left hemisphere. f
High-power detail of the ver-
mis. Arrow in d indicates silver
grain containing secretin
receptor-expressing Purkinje
cell, arrow in e shows a secretin
receptor-expressing cell in the
molecular layer, arrowheads
show labeled cells in the granular
cell layer. Abbreviations: Gr
granular cell layer, Mol molecu-
lar layer, P Purkinje cell, WM
white matter. Scale, 250 μm in a
and b, and 30 μm in c–f
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participation of the cerebellum in the stereotypic movements
was also suggested. With the use of magnetic resonance
imaging, Pierce and Courchesne (2001) observed that the
size of the VI and VII lobes of the cerebellar vermis is
negatively correlated with the seriousness of the repetitive
movements in autistic patients.
In our previous work, we investigated the effect of secre-
tin applied i.c.v. on the locomotor activity and on the ex-
plorative behavior in JWM and CFLP white mice. Our
animal model, JWM, showed a repetitive circular move-
ment, a stereotypic behavior which also occurs in several
mental disorders. Secretin strikingly improved the stereoty-
py. The animals exhibited more linear movement instead of
circular one. In the computerized analysis, it was indicated
by the enhancement of the ambulation distance during the
observation period. The secretin did not influence the ex-
plorative behavior which was indicated by rearing of ani-
mals. In our previous experimental conditions (Köves et al.
2011), none of the parameters were influenced by secretin in
the control CFLP white mice. In this present experiment, it
was found that i.n. application of secretin is even more
effective than the i.c.v. application to JWM.
It was supposed that secretin could exert its above-
mentioned effect through specific receptors. We looked for
secretin receptors in brain structures related to motor func-
tions. In the primary motor cortex and the striatum, only a
few neurons expressed secretin receptors; however, a dense
labeling was seen in the cerebellum. Our probe could mainly
detect secretin receptors in the granular cell layer; scattered
labeled cells were seen in molecular layer as well. A few
Purkinje cells were also labeled. Our results correlate with
those described by Yung et al. (2001, 2006). They demon-
strated secretin receptor labeling in the Purkinje and basket
cells of the cerebellar cortex and also showed that secretin
facilitated the GABAergic inhibitory inputs onto Purkinje
cells via a postsynaptic- and cAMP-dependent mechanism
as a retrograde messenger. A few years earlier, Nishijima et
al. (2006) demonstrated that secretin receptor-deficient mice
moved significantly faster than wild-type mice. In our spe-
cial animal model, the pattern of movement was changed by
administration of secretin. The untreated rats exhibited cir-
cular movement; however, the treated rats mainly exhibited
horizontal movement.
We have also seen considerable secretin receptor expres-
sion besides the cerebellum in the NST, the laterodorsal
thalamic nucleus, and lateral habenula (unpublished data).
The latter two structures belong to the limbic system. It is
also possible that secretin can influence the other aspects of
the behavior of animals, which was not investigated in our
work, through these structures. Nishijima et al. (2006) in-
vestigated not only the motor functions but among others,
the social behavior of secretin receptor mutant mice. They
used a tube for social dominance and partition test for social
interest and recognition. It was found that the mutant mice
exhibited abnormal social behavior.
In summary, our data show that secretin influences the
locomotor activity of a special animal model. Its effect on
the repetitive movement is beneficial. It normalizes the
horizontal movement (ambulation distance), although it
does not improve the explorative behavior of the animals.
It seems that the i.n. application is more effective than the
i.c.v. one; however, its overdosing had no effect. The pres-
ence of secretin receptors in the structures related to motor
function suggests that the effect of secretin is mediated
through these specific receptors.
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